<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> has been associated with an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study examines the effect of more vs less intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control on the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> 11,140 participants from the Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e>: Preterax and Diamicron-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> incidence and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality was compared in groups randomised to intensive or standard <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="4" pm="."><plain>Information on events during follow-up was obtained from serious adverse event reports and <z:hpo ids='HP_0011420'>death</z:hpo> certificates </plain></SENT>
<SENT sid="5" pm="."><plain>HRs (95% CI) were calculated for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> and site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]) </plain></SENT>
<SENT sid="7" pm="."><plain>The incidences of <z:hpo ids='HP_0000001'>all</z:hpo> solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93-1.27] for solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and 1.17 [0.75-1.84] for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>Across <z:hpo ids='HP_0000001'>all</z:hpo> the major organ systems studied, no significant differences in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidences were observed in the intensive and standard control groups </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATIONS: More intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control achieved with a regimen that included greater use of <z:chebi fb="0" ids="31654">gliclazide</z:chebi>, insulin, <z:chebi fb="0" ids="6801">metformin</z:chebi> and other agents, did not affect the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> events or <z:hpo ids='HP_0011420'>death</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>